MedTrace Logo

Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment

NCT04096547 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2020-10-22

No results posted yet for this study

Summary

Study Type and Design Prospective, Observational Study Rivaroxaban in Elderly AF patients with or without renal impairment in Korea

This study will investigate effectiveness and safety in elderly patients, the result from well-designed and high-quality prospective clinical registry collected through real-world clinical practice is expected to resolve current medical unmet needs of rivaroxaban in Korean elderly patients.

Primary Study Objective(s) To investigate the effectiveness of rivaroxaban in elderly patients with NVAF, with or without renal impairment in Korea real-world clinical practice settings Secondary Study Objective(s) To see safety outcome including major bleeding, clinically non-major bleeding, all-cause mortality rivaroxaban in subgroup based on risk factor(eg. Renal impairment) physicians' treatment pattern in rivaroxaban

Conditions

Interventions

DRUG

Rivaroxaban

rivaroxaban for stroke prevention of atrial fibrillation

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-25
Primary Completion
2022-02-28
Completion
2022-08-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096547 on ClinicalTrials.gov